James Welsh, MD
Radiation Oncology · Houston, TXNPI 1336359876
Payments from drug & device makers
What this record shows
This record is dominated by royalties or licence payments: $392,474 of the $420,849 with a category attached, or 93.3%. Alkermes, Inc. accounts for 93.8% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $400,655 and has fallen 99.9% since, to $339 in 2025. Among radiation oncology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 47 payments — averaging $8954.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$395K
- Roche Molecular Systems, Inc.$7K
- Reflexion Medical, Inc.$6K
- Novocure Inc.$5K
- AstraZeneca$3K
- Genentech, Inc.$3K
- plus $3K from 7 others
Across 35 payments — averaging $134,241 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$2.4M
- Siemens Medical Solutions USA, Inc.$421K
- Alkermes, Inc.$392K
- Novocure GmbH$387K
- Takeda Pharmaceuticals U.S.A., Inc.$380K
- Varian Medical Systems, Inc.$356K
- plus $360K from 3 others
What the payments were for
- Royalty or licence$392,47493%
- Consulting fees$7,9002%
- Speaking & faculty fees$11,5883%
- Travel & lodging$5,1541%
- Food & beverage$2,3061%
- Education$1,2500%
- Gifts$1780%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 3 | $394,574 |
| Roche Molecular Systems, Inc. | 15 | $6,825 |
| Reflexion Medical, Inc. | 11 | $5,556 |
| Novocure Inc. | 6 | $4,535 |
| AstraZeneca | 3 | $3,132 |
| Genentech, Inc. | 1 | $2,800 |
| IBA Proton Therapy, Inc. | 1 | $1,413 |
| Boehringer Ingelheim | 1 | $1,247 |
| Stemline Therapeutics Inc. | 2 | $241 |
| Zap Surgical Systems, Inc. | 1 | $160 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $146 |
| Accuray Incorporated | 1 | $113 |
| Viewray Technologies Inc | 1 | $108 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$420,849 in reported general payments places this provider in the 95th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other radiation oncology in Houston
- Stephen ChunHouston$344K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Abhilasha PatelHouston$76K
- Joe ChangHouston$50K
- Daniel GomezHouston$47K
- David RosenthalHouston$40K
- Andrew FarachHouston$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.